retatrutide phase 2 nejm weight loss 48 weeks percent surmount-1 tirzepatide 2022 Tirzepatide for Obesity: Highlights from the SURMOUNT-1 Trial Retatrutide study sees significant weight

B12 is absorbed well from the fatty layer, so the vitamin reaches the bloodstream either way

#Cardiology #Hypertension #Jeraygo #Idorsia #PharmaNews #CanadianHealth #DrugApproval #ResistantHypertension #InnovationInMedicine #PublicHealth #PatientCare To view or add a comment, sign in INDUSTRY NEWS | Sun Pharma Scores Big: DCGI Clears Noveltreat Weight Loss Injection for India

The last clinical review was completed on 15/02/2026, with the next review scheduled for 15/02/2027.

To qualify, Ro patients must have a body mass index (BMI) of 2730 or higher and at least one weight-related health condition, such as type 2 diabetes, high cholesterol or high blood pressure

Okusa, M

The role of GLP-1 RA as a novel therapeutic option for managing T2DM needs to be further emphasized among the medical fraternity, considering the limited awareness regarding the role and biological action of GLP-1 RA among the HCPs in India